111 results about "PAPILLOMAVIRUS HUMAN" patented technology

The present invention relates to compounds of formula (I), in particular their use as degradation agents for the human papilloma virus E7 protein: # imgabs0 #

We queried DNA from saliva or plasma of 93 HNSCC patients, searching for somatic mutations or human papillomavirus genes, collectively referred to as tumor DNA. When both plasma and saliva were tested, tumor DNA was detected in 96% (95% CI, 84% to 99%) of 47 patients. The fractions of patients with detectable tumor DNA in early- and late-stage disease were 100% (n=10) and 95% (n=37), respectively. Saliva is preferentially enriched for tumor DNA from the oral cavity, whereas plasma is preferentially enriched for tumor DNA from the other sites. Tumor DNA in the saliva and plasma is a valuable biomarker for detection of HNSCC.

The invention relates to the technical field of gene detection, in particular to a primer and probe combination and a kit for detecting human papilloma virus nucleic acid 14 typing based on a digital PCR (polymerase chain reaction) method and application of the primer and probe combination and the kit. 14 HPV high-risk types including human papilloma viruses HPV52, HPV35, HPV18, HPV66, HPV39, HPV56, HPV68, HPV16, HPV31, HPV58, HPV59, HPV33, HPV45 and HPV51 can be quantitatively detected by utilizing a micro-droplet digital PCR method, compared with the prior art, the quantitative detection of more HPV types can be realized, the specificity is strong, the sensitivity is high, the lowest detection limit is reduced to 0.1 copies / uL, and real absolute quantification is realized.

Described herein is an immortalized mammalian cell configured for production of a bioproduct of interest, which cell has a safe harbor locus selected from an Adeno Associated Virus 1 (AAVS1) locus, a CCR5 locus, and a Rosa26 locus into which a Human Papillomavirus (HPV) E6 gene sequence and an HPV E7 gene sequence have been inserted. Also disclosed herein are methods for immortalizing a mammalian cell for production of a bioproduct of interest as well as methods of producing a bioproduct of interest.

The present application relates to the field of molecular biology, in particular to a primer probe composition, kit and detection method for 23 human papilloma virus genotyping detection, wherein the hydrolysis probe and molecular beacon probe are respectively designed in two different regions of HPV gene sequence E6 and L1, and the fluorescence collection point in the amplification stage is set in the high-temperature denaturation stage, so that the detection in the amplification stage and the melting curve stage is independent and does not interfere with each other, thereby realizing the combined use of real-time fluorescent PCR amplification detection technology and melting curve technology; the technology improves the single-well detection target flux of fluorescent PCR analysis technology, reduces the detection cost, and provides a more optimal detection method for HPV multiplex fluorescent PCR genotyping detection.

The invention provides a TCR (T cell receptor) capable of being specifically combined with an HPV-16E7 protein 11-19 amino acid (sequence: YMLDLQPET) peptide fragment. The peptide fragment and HLA-A * 02 can form a compound to exist on the surface of an HPV-16 infected cell. The invention also provides a nucleic acid molecule for coding the TCR and a carrier containing the nucleic acid molecule. In addition, the invention also provides a cell for transducing the TCR.

The invention discloses a human papilloma virus mRNA (messenger ribonucleic acid) detection kit for auxiliary diagnosis of cervical cancer patients. The human papilloma virus mRNA detection kit comprises a nucleic acid probe group and a series of nucleic acid probes AMP1-AMP5, wherein the nucleic acid probe group is used for being combined with a human papilloma virus mRNA target, and the nucleic acid probes AMP1-AMP5 are used for signal amplification. The human papilloma virus mRNA detection kit provided by the invention can assist pathologists in identifying and diagnosing cervical cancer patients, and provides a basis for clinicians to formulate a therapeutic schedule.

The application discloses a marker group for cervical cancer screening and diagnosis and application thereof, and belongs to the field of molecular biological technology.The marker group comprises at least four polypeptides shown in sequences of SEQ ID NO.1-42.The marker group constructed by the application has more excellent sensitivity and specificity when used for auxiliary diagnosis and early screening of cervical cancer.The auxiliary diagnosis result is superior to the efficiency (sensitivity 81.1%, specificity 78.9%) of combined detection of serum CEA, SCC-Ag and CA125 in early diagnosis of cervical cancer;the diagnostic sensitivity and specificity of serum cf-DNA are 72.2% and 81.7% respectively.The early screening result is also superior to the internationally recognized cervical cancer screening method, i.e., combined screening of cytological detection (TCT) and human papilloma virus (HPV) virology detection.

The invention provides a fabric cleaning agent with an anti-HPV effect and a preparation method thereof, and relates to the technical field of cleaning agents. According to the Gemini type quaternary ammonium salt surfactant composition disclosed by the invention, through the effects of the Gemini type quaternary ammonium salt surfactants with two specific structures, high synergy of washing and disinfecting functions is realized, excellent dirt-removing power can be achieved only by virtue of an optimized and compounded surfactant system, and biological enzymes which are easy to inactivate and difficult to stabilize do not need to be introduced; in a high-content surfactant system and in a weak acid environment, the compound still has an efficient and reliable antiviral effect on the human papilloma virus, and meets the dual requirements of public health and personal care; and the formula is mild and weakly acidic and fits the physiological environment of the skin, so that the use experience and the effect exertion are favorably improved.

The present application relates to the field of medicine, and specifically discloses a nine-valent human papillomavirus vaccine and its application. The nine-valent human papillomavirus vaccine includes truncated L1-VLP antigens of HPV6, 11, 16, 18, 31, 33, 45, 52, and 58, and an aluminum hydroxide adjuvant. The antigen components in the nine-valent HPV vaccine provided by the present invention are all derived from the main capsid protein L1 of HPV and are truncated. The truncated L1 protein expressed by the Escherichia coli system increases the yield of the L1 protein and reduces the production cost of the vaccine. The present application optimizes the particle size of each type of VLP antigen and the particle size of the aluminum hydroxide adjuvant, and controls the ratio of each type of VLP antigen and the aluminum hydroxide adjuvant, so that the obtained nine-valent HPV vaccine induces a high level of immune response, especially showing obvious effects in clinical practice, which is better than the effects of related vaccines currently on the market.

Immunogenic compositions and methods of use thereof, for eliciting an immune response against one or more virally driven cancers are described. The compositions typically include one or more viral antigens expressed in the virally driven cancers, or a nucleic acid encoding the same, and optionally one or more adjuvants. Preferably, the compositions include nucleic acids (e.g., mRNA) encoding one or more viral antigens. Exemplary antigens include those derived from a truncated form of the viral Large T Antigen (LTA) or Small T Antigen (STA) of Merkel Cell Polyomavirus (MCPyV), or E2, E5, or E6 proteins of HPV. Pharmaceutical compositions and dosages including one or more of the compositions and an excipient, and methods of immunizing subjects and priming and engineer T cells for use in adoptive therapy are also provided.

The application belongs to the technical field of detection, and relates to a human papilloma virus detection reagent and application thereof. The human papilloma virus detection reagent comprises human papilloma virus antigen coated magnetic microparticle reagent and alkaline phosphatase labeled human papilloma virus antibody reagent. The human papilloma virus antigen coated magnetic microparticle is sealed by a sealing agent which is mixed by 2-10wt% PEG6000 solution, DB1130 and 0.1-1wt% gelatin solution. The system for detecting human papilloma virus antibody adopted by the application fills the gap of domestic HPV chemiluminescence antibody detection, and has high sensitivity, accuracy and clinical value.

The application provides a primer probe combination for detecting HPV16 and HPV18 by using microdroplet digital PCR and application thereof, and belongs to the technical field of human papilloma virus detection products. The primer probe combination for detecting HPV16 and HPV18 by using microdroplet digital PCR comprises a multi-target primer probe combination for detecting HPV16, and a multi-target primer probe combination for detecting HPV18, wherein the nucleotide sequence of the primer probe combination for detecting HPV16 is shown in SEQ ID NO. 1-27, and the nucleotide sequence of the primer probe combination for detecting HPV18 is shown in SEQ ID NO. 28-54. The primer probe combination has high sensitivity and low detection limit, can accurately detect HPV16 and HPV18 with high specificity and low cost, accurately capture trace ctDNA in early cervical cancer patient samples, significantly improve the early diagnosis rate, and effectively avoid the missed detection risk of single detection.

The invention belongs to the technical field of pharmaceutical compositions, and relates to a small interfering RNA for treating cervical cancer and application thereof, the small interfering RNA comprises a first small interfering RNA and a second small interfering RNA, the first small interfering RNA is siE6 / E7, the siE6 / E7 is a nucleotide sequence as shown in a positive-sense strand of SEQ ID NO.7 and an antisense strand of SEQ ID NO.8, and the second small interfering RNA is a nucleotide sequence as shown in a positive-sense strand of SEQ ID NO.7 and an antisense strand of SEQ ID NO.8. The second small interfering RNA comprises a positive-sense strand and an antisense strand which is in reverse complementary pairing with the positive-sense strand, the positive-sense strand comprises nucleotide sequences as shown in SEQ ID NO.1, SEQ ID NO.3 and SEQ ID NO.5, and the antisense strand comprises nucleotide sequences as shown in SEQ ID NO.2, SEQ ID NO.4 and SEQ ID NO.6. The first small interfering RNA comprises a first small interfering RNA and a second small interfering RNA, and the second small interfering RNA comprises a positive-sense strand and an antisense strand which is in reverse complementary pairing with the positive-sense strand. The small interfering RNA designed by the invention can increase the anti-tumor activity of the human papilloma virus protein E6 / E7 small interfering RNA, and the anti-tumor activity of the E6 / E7 and CTBP co-knock-down treatment is obviously enhanced compared with the anti-tumor activity of the E6 / E7 and CTBP single knock-down treatment.

The present application provides antibodies or antigen-binding fragments thereof that target human papilloma virus. The invention also relates to application of the antibody or the antigen binding fragment thereof in treatment, prevention and / or diagnosis of human papilloma virus infection or diseases caused by human papilloma virus infection.

To provide virus-like particle drug conjugate formulations and use of the conjugates for treating ocular tumors or lesions.SOLUTION: The present disclosure provides, in some aspects, ophthalmic compositions comprising a virus-like particle (VLP) drug conjugate comprising photosensitive molecules conjugated to capsid proteins of a VLP and 2-(N-morpholino)ethanesulfonic acid (MES) or a pharmaceutically acceptable salt thereof. Surprisingly, the particular MES-based formulations provided herein eliminate visible aggregation and precipitation of the VLP drug conjugate, relative to other formulations tested, in some embodiments, without at a low salt concentration and / or with a pH that is suitable for ophthalmic administration (e.g., less than 7, such 6.5).SELECTED DRAWING: None

The invention relates to the technical field of molecular biology, in particular to a super-quenching probe and application thereof. According to the super-quenching probe provided by the invention, a quenching group ZEN is inserted into the 3-4 base sites in the middle of a nucleic acid sequence, so that the background of the MGB type probe is remarkably reduced, the signal-to-noise ratio is increased, and the detection sensitivity is higher in the actual qPCR application process. Compared with a common probe, when the super-quenching probe is applied to human papilloma virus detection, the super-quenching probe can show more excellent detection accuracy and sensitivity under the sample concentration of 1000 times.

The utility model belongs to the field of high-risk human papilloma virus detection, in particular relates to a disposable reagent feeding tube, and aims to solve the problems that when the conventional disposable reagent feeding tube is used, the dosage cannot be well controlled, so that the reagent quantities in multiple inspection processes are different, part of needle tubes with quantitative functions are higher in cost. According to the technical scheme, the reagent adding pipe comprises a reagent measuring cup and a reagent adding pipe body, the reagent adding pipe body and the reagent measuring cup are used in a matched mode, a piston block is connected into the reagent adding pipe body in a sliding mode, a piston rod is fixedly connected to the top of the piston block, and a second protruding plate is fixedly connected to the top of the piston rod. The second protruding plate is pulled to drive the piston rod and the piston block to move upwards, the reagent in the reagent measuring cup can be quantitatively extracted, the disposable design is adopted, cleaning and disinfection are not needed, the workload and cost are reduced, the reagent amount can be accurately controlled, the operation process is simplified, and therefore the detection efficiency can be greatly improved.

The invention belongs to the field of molecular diagnostic biology, and relates to a primer probe combination, a kit and a detection method for simultaneously and quantitatively detecting 14 high-risk human papilloma viruses, primers comprise an HPV16 primer pair, an HPV18 primer pair, an HPV31 primer pair, an HPV33 primer pair, an HPV35 primer pair, an HPV39 primer pair, an HPV45 primer pair, an HPV51 primer pair, an HPV52 primer pair, an HPV56 primer pair, an HPV58 primer pair, an HPV59 primer pair, an HPV66 primer pair and an HPV68 primer pair; the probes comprise an HPV16 probe, an HPV18 probe, an HPV31 probe, an HPV33 probe, an HPV35 probe, an HPV39 probe, an HPV45 probe, an HPV51 probe, an HPV52 probe, an HPV56 probe, an HPV58 probe, an HPV59 probe, an HPV66 probe and an HPV68 probe. According to the application, 14 high-risk human papilloma virus nucleic acids (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68 types) in extracted cervical exfoliated cells can be quantitatively detected, the HPV16 and 18 types can be distinguished, absolute accurate quantitative analysis of the HPV is realized, and the detection sensitivity and accuracy are improved.

Single-domain antibodies that specifically bind human papillomavirus (HPV) E6 or E7 oncogenic peptides in complex with human major histocompatibility complex (MHC) proteins are described. The E6-MHC-specific and E7-MHC-specific single-domain antibodies were isolated from dromedary camel (VHH) antibody libraries by panning the library with an E6- or E7-derived peptide in complex with HLA-A*02:01. Use of the single-domain antibodies for the detection and treatment of HPV-associated cancers and pre-cancerous lesions is also described.

The invention provides a construction and preparation method of a novel HPV fusion protein antigen and an application of the novel HPV fusion protein antigen in preparation of a polyclonal egg yolk antibody. Core antigen peptides of human papilloma virus 16 subtype and HPV 18 subtype capsid protein L1 are respectively connected in series with an Fc of immunoglobulin IgY and a tail peptide of immunoglobulin IgM for the first time; the recombinant fusion protein antigen is prepared through escherichia coli expression and an inclusion body renaturation technology, the method is beneficial for improving the stability and presentation capacity of antigen peptide, laying hens are directly immunized with the purified novel HPV fusion protein antigen, after an antibody is generated, the antibody is purified through the steps of salting out, dialysis and the like, and the antibody is obtained. Verification shows that the obtained egg yolk antibody can be combined with L1 proteins of HPV16 and HPV18, and has the capability of preventing or treating infection of HPV16 and HPV18.

The present disclosure relates to compositions, kits, systems, and methods for detecting the presence or absence of human papillomavirus 16 (HPV16) or HPV18 nucleic acid (e.g., cell-free DNA) in a sample from a subject. In particular embodiments, a sample is contacted with at least one set of oligonucleotide having a forward primer, reverse primer, and a detectable labeled probe (e.g., for detecting PCR generated amplicons). In certain embodiments, the amount of HPV16 or HPV18 in the sample is quantitated (e.g., quantitative PCR is employed).

The present invention relates to a combination of markers for detecting human papillomavirus (HPV) in a cervical sample, wherein said combination of markers comprises a first marker selected from MUC5B and / or TFF3 for verifying the reliability of the cervical sample, wherein the expression of the first marker indicates that the cervical sample comprises cells from the cervical transition zone and / or endocervical canal; and a second marker for detecting HPV. Further, the present invention relates to a method for verifying the reliability of a biological sample, as well as a method for detecting HPV in a biological sample, based on the analysis of the one or more markers selected from MUC5B and / or TFF3. Also provided is the use of the novel markers of the invention for verifying the reliability of a biological sample. Furthermore, provided are methods for screening of sexually transmitted infections (STI) and of dysplastic / neoplastic lesions in a biological sample. The present invention also provides a kit of parts for the above-mentioned methods.

The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus. The present invention also relates to the pharmaceutical compositions containing the compounds of Formula (I) for the treatment of cancers associated with human papillomavirus.

Disclosed in the present invention are a self-replicating messenger ribonucleic acid (mRNA) sequence and a use thereof in preparation of an anti-human papillomavirus (HPV) tumor drug. A self-replicating mRNA base comprises a sequence as shown in at least one of SEQ ID NO: 8, SEQ ID NO: 13, and SEQ ID NO: 15. In the present invention, mutation and tandem design is carried out on the basis of E6 and E7 proteins, thereby improving the immunogenicity of E6 and E7 proteins expressed by an mRNA, and overcoming the pain point problem in the traditional technology of E6 and E7 proteins for vaccines being difficult to be effectively recognized by a human immune system.

The present invention relates to a human papillomavirus antigen peptide and its application, belonging to the technical field of immunomedicine. The antigen peptide comprises the amino acid sequence shown in SEQ ID NO.1, or a small peptide having more than 90% similarity to the amino acid sequence shown in SEQ ID NO.1. The above-mentioned human papillomavirus antigen peptide is a new target located in the E7 gene of the HPV16 genome. This target is not expressed in normal human tissues during viral genome expression and can be used as an antigen target for applications in reagents, drugs, or vaccines for the diagnosis, treatment, and prognosis determination of clinical HPV16 / 18 infections or HPV16 / 18-positive tumors such as cervical cancer, esophageal cancer, head and neck cancer, oropharyngeal cancer, anogenital cancer, etc. For example, through adoptive T cell immunotherapy, it may bring new treatment possibilities to patients with advanced recurrent cervical cancer.

The application relates to a primer probe composition and application for human papilloma virus nucleic acid typing detection. The primer probe composition comprises one universal label primer and 28 groups of primer probe groups respectively used for detecting 28 human papilloma virus nucleic acid types; wherein each group of the primer probe group comprises one upstream primer, one downstream primer and one probe, and the 5' ends of the upstream primer and the downstream primer are marked with the universal label primer, and the base sequence of the universal label primer is shown as SEQ ID NO: 59. The primer probe composition or kit can realize single-tube and simultaneous detection of 28 HPV subtypes, has high detection accuracy, good sensitivity and specificity, and the whole detection process can be automatically realized by using a full-automatic device.

The present application provides formulations of an enhanced antigen presenting cell ("enhanced APC"), where the formulations comprise: the enhanced APC comprising an antigen (e.g., human papilloma virus (HPV) antigen) and one or more of: cryopreservation medium, cryopreservation medium, and human serum albumin. Also provided herein are methods of producing such formulations and the enhanced APCs.

The application discloses a recombinant protein of human papillomavirus type 52 L1 protein, and the amino acid sequence of the recombinant protein is the amino acid sequence of human papillomavirus type 52 L1 protein (1-141) with a His tag at the N terminal, wherein the amino acid sequence of human papillomavirus type 52 L1 protein (1-141) is shown as SEQ ID NO:1; the recombinant protein is applied to preparation of a reagent for detecting human papillomavirus type 52 infection, and can be used for detecting whether HPV52 antibodies exist in a vaginal washing liquid of a to-be-detected person; the method has the characteristics of high sensitivity and specificity, wide application, and is not dependent on large equipment, and has strong universality.

This disclosure provides a method for evaluating the prognosis of a head and neck cancer patient. The head and neck cancer may be human papillomavirus positive (HPV+) and originate in the upper aerodigestive tract (e.g. oropharynx, nasopharynx, nasal cavity, sinus, or hypopharynx). In addition, the disclosure provides a method for predicting a response of a head and neck cancer patient to a selected treatment. The disclosure also provides a method for generating an improved head and neck cancer biomarker signature for patient prognosis and uses thereof.